Fidelity Contrafund

Fidelity Contrafund is one of the largest and most prominent actively managed mutual funds in the United States, managed by Fidelity Investments. Launched in 1967, the fund primarily seeks long-term capital appreciation by investing in companies whose value the management believes is not fully recognized by the public. While it is a financial investment vehicle rather than a life sciences company, it is a major institutional investor in the healthcare, biotechnology, and pharmaceutical sectors. The fund is notably managed by Will Danoff, who has overseen its growth strategy since 1990. It frequently participates in late-stage private equity crossover rounds for emerging biotech firms prior to their initial public offerings.